About quanterix corp - QTRX
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.
QTRX At a Glance
Quanterix Corp.
900 Middlesex Turnpike, Building 1
Billerica, Massachusetts 01821
| Phone | 1-617-301-9400 | Revenue | 137.42M | |
| Industry | Medical Specialties | Net Income | -38,531,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 12.301% | |
| Fiscal Year-end | 12 / 2025 | Employees | 471 | |
| View SEC Filings |
QTRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.968 |
| Price to Book Ratio | 1.242 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.527 |
| Enterprise Value to Sales | 1.136 |
| Total Debt to Enterprise Value | 0.239 |
QTRX Efficiency
| Revenue/Employee | 291,764.331 |
| Income Per Employee | -81,806.794 |
| Receivables Turnover | 4.276 |
| Total Asset Turnover | 0.327 |
QTRX Liquidity
| Current Ratio | 8.656 |
| Quick Ratio | 7.875 |
| Cash Ratio | 6.883 |
QTRX Profitability
| Gross Margin | 60.474 |
| Operating Margin | -38.288 |
| Pretax Margin | -27.723 |
| Net Margin | -28.039 |
| Return on Assets | -9.171 |
| Return on Equity | -11.333 |
| Return on Total Capital | -10.487 |
| Return on Invested Capital | -10.277 |
QTRX Capital Structure
| Total Debt to Total Equity | 11.323 |
| Total Debt to Total Capital | 10.171 |
| Total Debt to Total Assets | 9.076 |
| Long-Term Debt to Equity | 9.882 |
| Long-Term Debt to Total Capital | 8.877 |